Introduction
With the evolution of successful cancer treatments, the mortality rate of cancer patients has decreased. However, the evidence of increased cardiotoxicity that develop due to the conventional chemotherapy drugs 1, 2 and the newly developed anticancer therapies 3, 4 has led to the emergence of onco-cardiology field. [5] [6] [7] Fortunately, the treatment outcomes for cancer patients have improved, and additionally, awareness has increased regarding cardiovascular disease in cancer survivors. 8 Growing evidence for the damage caused by cancer treatments has indicated the need for monitoring the cardiovascular system after a cancer diagnosis; in line with this, there is increasing co-operation between tumour experts and cardiovascular experts. 9, 10 The acute-phase mortality rate of acute myocardial infarction (MI) is approximately 6-8%. [11] [12] [13] In patients with coronary artery disease (CAD), coronary revascularization is the most commonly used surgery to improve lifetime prognosis and quality of life. 14 Percutaneous coronary intervention (PCI) is a non-surgical technique that improves the survival rate of patients with ST-segment elevation MI, 15, 16 and it has
shown to improve the long-term survival of non-ST-segment elevation MI patients, thereby reducing the early and the late cardiac events. 17, 18 Percutaneous coronary intervention comprises plain old balloon angioplasty (POBA), bare metal stent (BMS), and drug-eluting stent (DES) methods, and aspiration and excimer laser coronary angioplasty, among other techniques, may be added to them. To date, although many studies on the prognosis after PCI have been conducted, [19] [20] [21] [22] no studies have been published to compare the prognosis of patients receiving PCI between the malignant and the non-malignant groups. When surgery is needed in patients with malignant diseases requiring PCI, revascularization is often performed after surgery due to the use of anti-thrombotic agents, but the optimal timing of revascularization has never been examined. Thus, the Kumamoto University Malignancy and Atherosclerosis (KUMA) study was designed to evaluate the concurrence rate and clinical outcomes in patients following PCI.
Methods
The KUMA study was a retrospective, single-centre, observational study that explored the clinical outcomes after PCI in patients with cancer or with a history of cancer. This study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000028652) (http://www.kumadai-junnai.com/home/wp-content/uploads/akusei.pdf).
Ethics statement
All procedures were conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the institutional review board of Kumamoto University.
Study population
The KUMA study included 1713 consecutive PCIs at Kumamoto University Hospital between January 2007 and December 2014. We excluded the following patients: 642 duplication patients, 11 patients who succumbed to in-hospital death, 344 non-DES patients (239 BMS, 67 BMS þ DES, 28 POBA, 4 aspiration, 2 POBA þ aspiration, 2 PCI failure, 1 excimer laser coronary angioplasty, and 1 unknown), and 15 patients who were identified as having a malignancy after PCI. The remaining 701 DES-only PCI patients were enrolled ( Figure 1 ). Acute coronary occlusion, which was a problem in the balloon catheter-only era, was overcome with the advent of the BMS. With the development of the DES, in-stent restenosis, which was a problem associated with the BMS, was highly reduced. 23 Therefore, in this study, we decided to examine the effect of restenosis on malignant diseases in DES-only cases. We reviewed the medical records and defined each patient's malignancy status, including the medical history of previous and current cancer types, and whether they currently had disease, had completed treatment within a year, or completed treatment more than 1 year ago. We divided the enrolled patients into 4 groups according to the timing of the treatment: NM = non-malignant, CC = currently has cancer, RC = recent cancer (within a year), NRC = non-recent cancer (more than a year ago) groups.
Clinical parameters
Baseline demographic data, cardiovascular risk factors, and medications on discharge after their PCI were documented. Hypertension was defined as the patients with blood pressure >140/90 mmHg or taking antihypertensive medication. Diabetes mellitus (DM) was defined as the presence of symptoms of diabetes and a casual plasma glucose concentration > _200 mg/dL, fasting plasma glucose concentration > _126 mg/dL, and 2-h plasma glucose concentration > _200 mg/dL from a oral glucose tolerance test (75 g), or taking medication for DM. Dyslipidaemia was defined as low-density lipoprotein > _140 mg/dL (> _3.63 mmol/L), high-density lipoprotein <40 mg/dL (1.04 mmol/L), or triglycerides > _150 mg/dL (> _1.7 mmol/L). Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) < 60 mL/min/ 
Follow-up
After PCI, patients were followed up prospectively at the outpatient clinics for 1 year or until an endpoint occurred. The primary endpoint was target lesion revascularization (TLR) within 1 year. The follow-up period was 1 year, but for some patients, the follow-up period occurred sooner because they had a cardiovascular event, meaning that the follow-up period in reality was between 6 and 365 days depending on the outcome of an individual's PCI. At 1-year follow-up, we measured the total number of first TLR events and stopped the analysis. The secondary endpoints were the total cardiovascular events (defined as cardiovascular death, non-fatal MI, unstable AP, TLR, non-TLR, and hospitalization for heart failure decompensation) and all-cause death. Cardiovascular events were ascertained from a review of medical records and confirmed by direct contact with the patients, their families, or physicians. Cardiovascular death was defined as death due to MI or congestive heart failure or as documented sudden cardiac death. For the purpose of this study, we used the universal definition of MI. 26 For patients who had suffered more than one cardiovascular events, only the first event was counted as an event.
Statistical analysis
The Shapiro-Wilk test was used to assess the normal distribution of continuous data. Continuous variables with a normal distribution were expressed as the mean ± standard deviation, whereas those with skewed distributions were expressed as the median value with an interquartile range. Categorical data were presented as numbers or percentages.
Differences between two groups were tested using the Fisher's exact test or the v 2 test for categorical variables, as appropriate. Differences in continuous variables were analysed with an analysis of variance. We used the Kaplan-Meier method to estimate the cardiovascular event probabilities at 365 days and the log-rank test to compare the distributions of survival times among groups. Cox proportional hazard models were used to calculate the hazard ratios (HRs). Multivariate analyses were performed by stepwise backward and forced inclusion methods with previously reported conventional risk factors (CRFs) 27 comprising age, male gender, hypertension, diabetes, dyslipidaemia, and current smoking status. Receiver operating characteristic (ROC) curves for risk factors were drawn and the estimates of the C-statistic for risk factors were calculated before and after the addition of malignancy and hs-CRP to the model of CRFs. The incremental effect of adding the malignancy and hs-CRP to the model of CRFs in predicting future cardiovascular events was evaluated using the net reclassification improvement (NRI) as previously described. 9 A P-value <0.05 was considered to denote statistical significance. Statistical analyses were performed using SPSS version 22 (IBM Inc., Armonk, NY, USA).
Results

Study population and malignant disease incidence
Among the 701 enrolled DES-only patients, 114 (16.3%) patients [86 men (17.3%) and 28 women (3.7%)] had a medical history of malignant disease. The top three most common malignant diseases in female patients were breast, skin, and stomach cancer ( Figure 2A) , and the top three in male patients were prostate, stomach, and kidney cancer ( Figure 2B ).
Prevalence of co-morbidities among the study participants Table 1 presents the clinical characteristics of the study paticipants.
Compared with patients without malignancy, patients with malignancy were older, had a lower eGFR, had lower rates of dyslipidaemia, were more likely to be current tobacco users, and had higher rates of a previous MI. There was no significant difference in the levels of hs-CRP between the malignant and the non-malignant groups (0.088-0.50 vs. 0.09-0.58; P = 0.68). Concerning coronary and PCI details, we found no significant differences in the single, double, triple, and left main truncus lesions or in the rates of 1st DES, between the malignant and the non-malignant groups. In addition, there were no significant differences between groups in the frequency of medication usage (statins, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, beta-blocker, and proton pump inhibitors) upon discharge.
Increased risk of target lesion revascularization incidence in patients with a cancer history at 1-year follow-up
Data for 701 PCI patients were available for the analysis of subsequent adverse cardiovascular events. The follow-up period from discharge after PCI ranged from 6 days to 365 days (mean 326 days). At the 1-year follow-up, 61 (8.7%) patients had experienced TLR (15.8% in the malignant group and 7.3% in the non-malignant group; P = 0.006). The Kaplan-Meier analysis demonstrated a significantly higher probability of TLR (primary endpoint), total cardiovascular events, and all-cause death (secondary endpoints) in the malignant group than in the non-malignant group (P = 0.002, P = 0.003, and P = 0.018, respectively; Figure 3 ). This has led us to speculate that malignancy could be used as a predictive factor for increased risk of TLR and subsequent cardiovascular events. The incidence of TLR, stratified by cancer type, is described in Supplementary material online, Figure S1 .
Malignancy is an independent predictor of cardiovascular events Patients with both malignancy and high high-sensitivity C-reactive protein levels comprise a high-risk group for cardiovascular events
We found that the combination of malignancy and high hs-CRP levels was associated with significantly higher incidences of both TLR ( Figure 4A ) and total cardiovascular events ( Figure 4B ). Additionally, we analysed Cox proportional hazards for malignant status with high hs-CRP levels by adjusting the clinical parameters of CRFs and found increased HRs for both TLR (HR 3.01, 95% CI 1.57-5.76; P = 0.001) and total cardiovascular events (HR 2.15, 95% CI 1.27-3.66; P = 0.005).
Accuracy of malignancy status and high-sensitivityC-reactive protein levels in predicting recurrent cardiovascular events
By plotting an ROC curve, we estimated the C-statistic of CFRs alone as well as with the incorporation of malignancy and hs-CRP. Including malignancy and hs-CRP increased the C-statistic for the prediction of TLR and total cardiovascular events [0.59-0.65 ( Figure 5A ) and 0.59-0.64 ( Figure 5B ), respectively]. We then compared this new CRF model with the existing model using NRI. The NRI score was significant, showing that the inclusion of malignancy and hs-CRP improved the classification with respect to both primary and secondary endpoints (NRI 15.2%, 95% CI 4.3-26%; P = 0.02 and NRI 13.9%, 95% CI 1.7-28.4%; P = 0.03, respectively; Table 4 ).
Current or recent cancer treatment is associated with higher risk of recurrent cardiovascular events
We further evaluated the primary endpoints for each of the three patient groups with a history of cancer: CC (n = 17), RC (n = 34), and NRC (n = 63). As shown in Figure 6A and B, we found that patients in the CC and the RC groups experienced more TLR events within 1 year of follow-up. With regard to the correlation with inflammatory index, the hs-CRP level was significantly elevated in the CC group compared with the other groups (P = 0.028 by the Kruskal-Wallis 
Discussion
The results of this study showed that malignant disease was associated with an increased risk of adverse cardiovascular events following PCI in patients with CAD. A medical history of malignant diseases in patients undergoing PCI was positively correlated with an increased risk of TLR and total cardiovascular events as well as all-cause death within 1 year. Patients currently being treated for cancer with high levels of hs-CRP had worse prognoses than patients in the other subgroups. We also showed that it is possible to stratify the risk of a cardiovascular event by whether a patient currently has cancer or has had cancer in the past year. We did not investigate the biological basis for the increased rate of cardiovascular events that we found, but we speculate on the following. The report of a joint World Health Organization/Food and Agriculture Organization Expert Consultation concluded that overweight and obesity are established risk factors for adenocarcinoma of the oesophagus, 28 that a high salt intake is associated with gastric cancer, 29 and that diet-related factors may account for up to 80% of the differences in the rates of colorectal cancer among different countries. 30 Therefore, atherosclerotic diseases are often present, which complicates cancer treatment. 31, 32 Because some types of cancer and coronary atherosclerosis share certain lifestyle-related risk factors, such as hypertension and dyslipidaemia, it would be reasonable to expect that arteriosclerosis might be present in the coronary arteries of many patients with a malignant disease. Cancer 33 and atherosclerotic lesions 34 (including CAD) are both characterized by inflammation. We believe that the important mechanisms underlying this association are risk factors common to both cardiovascular disease and cancer and that inflammation is likely to be a candidate. For example, one might speculate that local malignancies might increase vascular wall inflammation through the action of inflammatory cytokines and that this circulatory inflammation might then cause progressive coronary arteriosclerosis. From these ideas, we have reported that the extent of coronary artery calcification is significantly increased in patients with malignant diseases. 9 In this study, we did not find the hs-CRP levels to significantly differ depending on the history of malignant disease, but found that cardiovascular events occurred more frequently in patients with both a history of malignant disease and higher values of hs-CRP levels when the patients were stratified by high and low hs-CRP levels. Moreover, an improvement in the predictive model for cardiovascular events was observed by adding malignancy and hs-CRP levels to the CRFs that can predict cardiovascular events. One might speculate that a patient undergoing treatment for cancer might be experiencing a systemic inflammatory reaction, which is reflected by the high hs-CRP levels and would suggest an increased risk of concurrent cardiovascular events. Furthermore, recently, the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS), trial 35 revealed that cardiovascular events and cancer incidence and mortality were decreased by canakinumab, an anti-inflammatory drug used in patients with arteriosclerotic diseases. These results offer major evidence to support our results. Thus, the results of this study suggest that active cancer in these patients can be attributed to inflammation caused by coronary arteriosclerosis due to the CRFs (such as obesity, diabetes, and dyslipidaemia) and cancer itself (such as carcinogenicity, hyperviscosity, and endothelial dysfunction).
In this study, there were significant differences for dyslipidaemia, eGFR, and smoking between the malignant and the non-malignant groups. With respect to dyslipidaemia, malignant tumour patients were thought to generally have malnutrition. The tendency to have a low body mass index in the malignancy group supported this finding. The eGFR might be affected by older age in the malignant group, and the differences in smoking might have been because patients with malignancy were more often instructed to quit smoking than were patients in the other groups.
The other possible underlying mechanism was thought to be the influence of radiotherapy because it is well known that radiotherapy, especially thoracic radiotherapy, promotes atherosclerosis. 36 In this study, the possibility of synergistic relationship between radiotherapy and TLR was speculated (see Supplementary material online, Figure  S2 ). Thus, further large-scale examination is desirable. 'Onco-cardiology' and 'cardio-oncology' are specialized medical terms that have been used to indicate the necessity of treatment for cardiotoxicity in patients with malignant diseases.
1,2 These concepts have recently been reviewed. [37] [38] [39] Indeed, we have also experienced the importance of onco-cardiology in clinical practice. 3, 4 However, probably due to the long survival of patients with malignant disease, cardiovascular disease commonly occurs concurrently with a malignant disease, and this complicates the course of treatment in clinical practice. 9, 31, 38 Although studies available in the literature have not systematically classified the relationship between traditional cardiovascular risk factors and the development of malignant disease, we have already proposed a classification system based on various clinical scenarios in onco-cardiology. 10, 40 Our findings in this study indicate that current or prior malignancy significantly correlates with the likelihood of recurrent cardiovascular events after PCI. Previous studies evaluated bleeding events after PCI, 41 but to our knowledge, this is the first study to evaluate the cardiovascular events following PCI in cancer. In this study, we found a close association between the malignant disease and the risk of recurrent cardiovascular events. Particularly, as shown in Figure 3 , TLR was most prevalent in these results, despite the DES use rate, including the 1st DES rate being similar between the malignant and the nonmalignant groups. We also observed that patients with a current or recent cancer history had a higher incidence of TLR within the follow-up period. Although the mechanism underlying this association is unknown, we propose that a more recent completion of cancer treatment might result in a higher level of systemic inflammation, which might in turn increase the risk of cardiovascular events. Taken together, these results suggest that caution should be taken by cardiologists when considering PCI in patients with a recent cancer history. Although it is common to perform PCIs after surgeries from the viewpoint of anti-thrombotic therapy in patients who were deemed to require PCIs by preoperative examination, our results suggest that many restenosis events might occur after the PCIs in these patients. A prospective randomized trial is now warranted to investigate whether postponing PCI to allow more recovery time from surgery would improve the cardiovascular prognosis. The speculated action of inactive and active cancer on coronary arteries is demonstrated in Figure 7 .
Study limitations
This study was a single-centre observational study, performed in a university hospital which, despite using relatively small patient numbers, included patients from a large catchment area and thus included a high number and a wide range of cancers among the patients studied, reflecting the broader incidence seen nationally and/or worldwide. It is not impossible that the clinical endpoints observed in this study were influenced by medications, and the possibility of the accompanying the use of anticancer agents cannot be neglected. Because there was no significant difference in the hs-CRP levels between the malignant and non-malignant groups (Table 1) parameters other than CRP, such as interleukins and tumour necrosis factor-alpha, might affect the main results of this study. However, these parameters were not measured in this study. Hence, further examination is necessary to avoid risks. The specific factors influencing the association between cancer and cardiovascular risk are unclear, and the extent to which these factors may contribute to the development of coronary artery atherosclerosis and the promotion of malignant diseases is unknown. Thus, further pathophysiological and molecular physiological studies, including animal experiments, are warranted. Moreover, we believe that additional large-scale clinical studies may be required to verify our speculations, particularly with regard to the potential benefits of tailoring cardiovascular treatment based on a patient's cancer history.
To realize the original purpose of onco-cardiology, co-operation among oncologists, cardiologists, and all other medical professionals associated with cancer care is crucial. Importantly, collaboration among education, medical treatment, and research professionals at academic and administrative levels as well as individual collaborations at medical sites is currently insufficient, and the establishment of team medical care is necessary. The concurrence of cardiovascular diseases and malignant diseases should be carefully considered in a clinical setting, particularly with regard to scheduled surgical procedures. Moreover, it is essential that oncologists are knowledgeable about this association. 
